SCHEMBL1001298

SCHEMBL1001298

COc1ccccc1NC(=O)c1cccc(S(=O)(=O)C2CCCCC2)c1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
KDM4E B2RXH2 3/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
HTT P42858 1/20 0.52
CNR2 P34972 1/20 0.52
SIRT2 Q8IXJ6 1/20 0.51
TP53 P04637 2/20 0.50
LMNA P02545 2/20 0.50
MAPT P10636 1/20 0.50
MAPK1 P28482 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17479118 0.87 POLB (0.44) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL1000620 0.83 KIF18A (0.48) KMT2AMEN1SMN1; SMN2HTTMAPK1
SCHEMBL1001949 0.81 MEN1 (0.67) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL1003903 0.80 ALDH1A1 (0.76) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL16903002 0.80 SMN1; SMN2 (0.62) ALDH1A1KMT2AMEN1SMN1; SMN2SIRT2
SCHEMBL1001386 0.80 MEN1 (0.61) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL1001469 0.80 ALDH1A1 (0.60) ALDH1A1KDM4EKMT2AMEN1HTT
SCHEMBL17479254 0.77 TP53 (0.54) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL17128989 0.77 HTR2B (0.63) ALDH1A1KDM4EKMT2AMEN1SMN1; SMN2
SCHEMBL2565722 0.77 AKR1C3 (0.51) ALDH1A1KMT2AMEN1SMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104352492-B Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient MSD K.K.公司 2017-12-05 CN disclosed
CN-104352492-A Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD KK 2015-02-18 CN disclosed
EP-2280001-B1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD KK (JP) 2014-10-15 EP disclosed
US-8420823-B2 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient MSD K.K. (JP) 2013-04-16 US disclosed
EP-2280001-A1 LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT Banyu Pharmaceutical Co., Ltd. (JP) 2011-02-02 EP disclosed
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT MSD K.K. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009622-A1 LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT ELOVL1, ELOVL6, ELOVL3 ALDH1A1 188/4885KDM4E 1335/4885KMT2A 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.